COMPANY

Aspa Therapeutics

Aspa Therapeutics is listed on ClinicalTrials.gov as the lead sponsor of 2 studies; the most recently updated is “A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)” (Phase 1, Phase 2, recruiting), in Canavan Disease. From public records Source · Oct 12, 2026

Keywords: Gene Therapy Canavan disease AAV9 BBP-812

Profile checked Oct 10, 2026

2Trials (company is sponsor)

Timeline

Sep 8, 2021 Trial start Phase 1/Phase 2: A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial) source ↗
Oct 10, 2019 Trial start —: Natural History Study of Patients With Canavan Disease (CANinform Study) source ↗

Upcoming milestones

Oct 13, 2026 (ESTIMATED) · Phase 1/Phase 2 · A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial) · NCT04998396

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT04126005	Natural History Study of Patients With Canavan Disease (CANinform Study)	Not listed	Completed	Oct 10, 2019	May 21, 2025 (actual)
NCT04998396	A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)	Phase 1/Phase 2	Recruiting	Sep 8, 2021	Oct 13, 2026 (estimated)